Generic Name and Formulations:
Pyridostigmine bromide 5mg/mL; soln for IV inj; contains benzyl alcohol.
Indications for REGONOL:
As a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.
Individualize. Give by IV inj. Usual range: 0.1–0.25mg/kg. Give atropine sulfate or equipotent dose of glycopyrrolate immediately prior to or simultaneously with Regonol.
Intestinal or urinary obstruction.
Bronchial asthma. Cardiac dysrhythmias. Electrolyte imbalance. Adrenal cortical insufficiency. Renal impairment. Neonates. Pregnancy (Cat.C).
Concomitant 4-aminopyridine may delay onset. Possible resistance to reversal with antibiotics associated with paralysis (eg, aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate). Recurrent paralysis possible with quinidine. Magnesium salts may enhance neuromuscular blockade and interfere with restoration.
GI upset, increased salivation and bronchial secretions, miosis and diaphoresis, muscle cramps, fasciculation and weakness, rash.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Models Predict Intracerebral Hemorrhage Growth
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy